Fulltext

Successful Booster Antibody Response up to 54 Months after Single Primary Vaccination with Virosome-Formulated, Aluminum-Free Hepatitis A Vaccine

Beck, Bernhard R. ; Hatz, Christoph ; Brönnimann, Rainer ; Herzog, Christian

In: Clinical Infectious Diseases, 2003, vol. 37, no. 9, p. e126-e128

Ajouter à la liste personnelle
    Titre
    • Successful Booster Antibody Response up to 54 Months after Single Primary Vaccination with Virosome-Formulated, Aluminum-Free Hepatitis A Vaccine
    Auteur
    • Beck, Bernhard R.. Swiss Tropical Institute, Basel
    • Hatz, Christoph. Swiss Tropical Institute, Basel
    • Brönnimann, Rainer. Berna Biotech, Berne, Switzerland
    • Herzog, Christian. Berna Biotech, Berne, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Clinical Infectious Diseases, 2003, vol. 37, no. 9, p. e126-e128. The University of Chicago Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:300018
    Summary
    This study demonstrates that a booster dose of the virosome-formulated, aluminum-free hepatitis A vaccine Epaxal (Berna Biotech) is highly immunogenic in subjects who received a single primary dose of this vaccine 18-54 months earlier. There were no significant differences in geometric mean antibody titers (GMTs) among subjects who received the booster dose 18-29 months (GMT, 2330 mIU/mL), 30-41 months (GMT, 2395 mIU/mL), or 42-54 months (GMT, 2432 mIU/mL) after primary vaccination, indicating that delays in the administration of booster vaccination do not lead to a loss of immunogenicity